SCHEMBL7572499

SCHEMBL7572499

CC(C)(C)OC(=O)NCc1cccc(NN=C(OS(=O)(=O)c2ccccc2)C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
BRD4 O60885 2/20 0.42
CA2 P00918 1/20 0.40
CCKBR P32239 1/20 0.40
GLS O94925 3/20 0.40
BRD9 Q9H8M2 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
RORC P51449 1/20 0.38
F2 P00734 2/20 0.38
TMPRSS6 Q8IU80 2/20 0.38
KLKB1 P03952 1/20 0.38
NAMPT P43490 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
AURKA O14965 1/20 0.38
RPS6KB1 P23443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7569209 0.93 BRD4 (0.43) CA1CA12CA7CA14BRD4
SCHEMBL7568747 0.88 BRD4 (0.44) CA1CA12CA7CA14BRD4
SCHEMBL7564751 0.79 BRD4 (0.47) CA1CA12CA7CA14BRD4
SCHEMBL3509267 0.74 BRD4 (0.52) CA1CA12CA7CA14BRD4
SCHEMBL10210711 0.73 BRD4 (0.51) CA1CA12CA7CA14BRD4
SCHEMBL7478429 0.73 BRD4 (0.48) BRD4CCKBRGLSNAMPTMEN1
SCHEMBL31709823 0.73 BRD4 (0.54) CA1CA12CA7CA14BRD4
SCHEMBL731764 0.73 BRD4 (0.54) CA1CA12CA7CA14BRD4
SCHEMBL29726453 0.72 CA2 (0.58) CA1CA12CA7CA14CA2
SCHEMBL8252977 0.72 CA2 (0.58) CA1CA12CA7CA14CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6465656-B2 ACYLATING/ACETYLATING ARYLHYDRAZINE, REACTING HYDROZONOYL HALIDE/SULFATE WITH AMINE BASE TO FORM 1-(3-CYANO)PHENYL-2-(TRIFLUOROACETYL)HYDRAZINE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-10-15 US disclosed
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-09 US disclosed
US-6329527-B1 ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP BRISTOL-MYERS SQUIBB PHARMA COMPANY 2001-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055641-A1 Synthesis of 1,3,5-trisubstituted pyrazoles TFPI, SERPINC1, F11 CA1 1253/4885CA12 3130/4885CA7 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.